A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: Metastatic Colorectal Cancer
• Intervention / Treatment: Drug: Botensilimab; Drug: Balstilimab; Drug: Standard of Care

Detailed Description

This study will enroll adult participants with a confirmed diagnosis of unresectable metastatic colorectal adenocarcinoma (CRC) who have had prior chemotherapy for metastatic or recurrent CRC.

This study will consist of 5 cohorts. In the first and second cohorts, participants will receive 1 of 2 different doses of botensilimab intravenously (IV) and balstilimab IV. In the third and fourth cohorts, participants will receive 1 of 2 different doses of botensilimab. In the fifth cohort, participants will receive standard of care consisting of the investigator's choice of regorafenib or trifluridine and tipiracil.

• Study Type: Interventional
• Enrollment (Estimated): 230
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Agenus, Inc.; Phone Number: 781-674-4265; Email: clinicaltrialinfo@Agenusbio.com

Study Locations

• Belgium
  • Edegem, Belgium, 2650
    • Antwerp University Hospital (UZA)
  • Leuven, Belgium, 3000
    • Universitair Ziekenhuis Leuven
• Brazil
  • Brasília, Brazil, 70200-730
    • Hospital Sirio Libanes Brasilia
  • Ijuí, Brazil, 98700-000
    • ONCOSITE - Centro de Pesquisa Clinica em Oncologia
  • Itajaí, Brazil, 88301-220
    • Catarina Pesquisa Clinica
  • Porto Alegre, Brazil, 90110-270
    • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
  • Pouso Alegre, Brazil, 37554-216
    • Instituto Sul Mineiro de Oncologia - ONCOMINAS
  • Rio de Janeiro, Brazil, 22775-001
    • Instituto Americas
  • São Paulo, Brazil, 01509-010
    • Hospital A.C. Camargo Cancer Center
  • São Paulo, Brazil, 04538-132
    • Centro Paulista de Oncologia
  • São Paulo
    • Jaú, São Paulo, Brazil, 17210-080
      • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
• France
  • Besançon, France, 25000
    • Service d'Oncologie Medicale - CHRU Besancon
  • Dijon, France, 21079
    • Centre Georges François Leclerc
  • Lyon, France, 69008
    • Centre Leon Berard
  • Marseille, France, 13009
    • Institut Paoli-Calmettes
  • Paris, France, 75012
    • Hôpital Saint Antoine/AP-HP Hopital Saint Antoine (Pierre and Marie Curie University)
  • Poitiers, France, 86000
    • CHU Poitiers - Pole Regional de Cancerologie de Poitiers (PRC)
  • Villejuif, France, 94805
    • Unversite Paris-Saclay Gustave Roussy Cancer Center Campus Paris
• Italy
  • Genova, Italy, 16132
    • IRCCS Azienda Ospedaliera Universitaria San Martino IST
  • Milano, Italy, 20162
    • ASST Grande Ospedale Metropolitano Niguarda
  • Milano, Italy, 20133
    • Fondazione IRCCS Instituto Nazionale Dei Tumori
  • Padova, Italy, 35128
    • Istituto Oncologico Veneto
  • Pisa, Italy, 56126
    • Azienda Ospedaliero Universitaria Pisana - Stabilimento di Santa Chiara
• Russian Federation
  • Barnaul, Russian Federation, 656045
    • RSBIHC "Altai Region Oncology Dispansery"
  • Chelyabinsk, Russian Federation, 454048
    • Limited Liability Company "EVIMED"
  • Krasnodar, Russian Federation, 350040
    • SBHI "Clinical Oncological Dispensary #1"
  • Kursk, Russian Federation, 305524
    • "Kursk Oncological Research and Clinical Center named after G. E. Ostroverkhova"
  • Moscow, Russian Federation, 111123
    • SBIH of the City of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Department of Health of the City of Moscow"
  • Moscow, Russian Federation, 115478
    • FSBI N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
  • Moscow, Russian Federation, 119991
    • FSAEI of HE I.M. Sechenov First Moscow State Medical University of the MoH of the RF
  • Moscow, Russian Federation, 121205
    • Branch office of " Hadassah Medical Ltd"
  • Novosibirsk, Russian Federation, 630099
    • Closed Joint Stock Company Medical Center "AVICENNA"
  • Omsk, Russian Federation, 644013
    • BHI of the Omsk region "Clinical oncological dispensary"
  • Orenburg, Russian Federation, 460021
    • SAHI "Orenburg Regional Clinical Oncological Dispensary"
  • Saint Petersburg, Russian Federation, 195271
    • "Clinical Hospital "RZD-Medicine" of Saint Petersburg"
  • Saint Petersburg, Russian Federation, 197758
    • Federal State Budgetary Institution "National Medical Research Center of Oncology named after N.N. Petrov" оf the Ministry of Health of the Russian Federation
  • Saint Petersburg, Russian Federation, 197758
    • State Budgetary Healthcare Institution "Saint-Petersburg clinical scientific and practical center for specialised types of medical care (oncological)"
  • Saint Petersburg, Russian Federation
    • Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology)
  • Tomsk, Russian Federation, 634028
    • Siberian State Medical University
• Spain
  • Barcelona, Spain, 8035
    • Vall d'Hebron Institute of Oncology (VHIO)
  • Madrid, Spain, 28041
    • Hospital Universitario 12 De Octubre
  • Madrid, Spain, 28027
    • Clinica Universidad de Navarra - Sede Madrid
  • Pamplona, Spain, 31008
    • Clinica Universidad de Navarra - Sede Pamplona
  • Santander, Spain, 39008
    • Hospital Universitario Marques de Valdecilla
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85258
      • HonorHealth Research Institute
  • California
    • Duarte, California, United States, 91010
      • City of Hope National Medical Center
    • Los Angeles, California, United States, 90033
      • Keck School of Medicine of the University of Southern California
  • Colorado
    • Aurora, Colorado, United States, 80012
      • Rocky Mountain Cancer Center - Aurora
    • Denver, Colorado, United States, 80220
      • University of Colorado
  • Delaware
    • Newark, Delaware, United States, 19713
      • Medical Oncology Hematology Consultants
  • Florida
    • Lake Mary, Florida, United States, 32746
      • Florida Cancer Specialists and Research Institute - Lake Mary
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Beth Israel Deaconess Medical Center
    • Boston, Massachusetts, United States, 02215
      • Dana-Farber Cancer Institute
  • Michigan
    • Ann Arbor, Michigan, United States, 48084
      • University of Michigan
  • New Jersey
    • Morristown, New Jersey, United States, 07960
      • Atlantic Health System - Morristown Medical Center
  • New York
    • New York, New York, United States, 10021
      • Weill Cornell Medical College
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering
    • New York, New York, United States, 10029
      • Mount Sinai Hospital - New York
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health & Science University (OHSU)
    • Portland, Oregon, United States, 97213
      • Earle A. Chiles Research Institute - Robert W. Franz Cancer Center - Providence Cancer Institute
  • Rhode Island
    • East Providence, Rhode Island, United States, 02915
      • Lifespan Clinical Research Center/Cancer Institute (Providence Rhode Island)
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Tennessee Oncology Nashville (Sarah Cannon)
    • Nashville, Tennessee, United States, 37215
      • Vanderbilt University School of Medicine
  • Texas
    • Austin, Texas, United States, 78705
      • Texas Oncology - Austin Midtown
    • Dallas, Texas, United States, 75246
      • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    • Houston, Texas, United States, 77030
      • MDACC
  • Virginia
    • Fairfax, Virginia, United States, 22031
      • Virginia Cancer Specialists/NEXT Virginia
  • Washington
    • Seattle, Washington, United States, 98104
      • Swedish Cancer Institute
    • Vancouver, Washington, United States, 98684
      • Northwest Cancer Center Specialists - Vancouver Cancer Center - Compass Oncology Vancouver

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Histologically confirmed diagnosis of unresectable and metastatic CRC adenocarcinoma.
2. The tumor must have been assessed for microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) status per a standard local testing method.
3. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures.

4. Must have received at least 1 prior chemotherapy regimen for metastatic or recurrent CRC as follows where approved and locally available in the country of randomization:

   1. Standard chemotherapy/therapy including all of the following agents (if eligible and no contraindication): a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab or biosimilars, an anti-epidermal growth factor receptor antibody (cetuximab or panitumumab), and v-raf murine sarcoma viral oncogene homolog B1 inhibitor/BRAF (encorafenib), if applicable.
   2. Participants must have progressed while receiving or within 3 months of the last administration of their last line of standard therapy or be unable to tolerate any of these standard treatments.
   3. Participants who received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy can count this as a line of therapy.
5. Measurable disease on baseline imaging per RECIST 1.1.
6. Life expectancy ≥ 12 weeks.
7. Eastern Cooperative Oncology Group performance status of 0 or 1.
8. Adequate organ function.
9. Women of childbearing potential must have a negative serum pregnancy test at screening and prior to study drug administration.
10. Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study, starting with the Screening visit through 2-6 months, depending upon assigned study treatment. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
11. No growth factor support, transfusions, or albumin administration within 14 days of randomization of study treatment.

Exclusion Criteria:

1. Tumor is MSI-H/dMMR per a standard local testing method.
2. Received programmed cell death protein 1, PD-(L)1, or CTLA-4 therapies including any immune checkpoint inhibitor or experimental immunologic agents.
3. Received regorafenib or trifluridine/tipiracil as prior therapy(ies).
4. Partial or complete bowel obstruction within the last 3 months, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction.
5. Refractory ascites.
6. Liver metastases by computed tomography or magnetic resonance imaging. Note: Participants with definitively treated liver metastases (this includes surgical resection, including microwave or radiofrequency ablation, or stereotactic body radiation therapy, but not yttrium-90 or chemotherapy alone) may be eligible if they were treated at least 6 months prior to enrollment with no evidence of metastatic disease in the liver on subsequent imaging.
7. Clinically significant (that is, active) cardiovascular disease.
8. Active brain metastases or leptomeningeal metastases with certain exceptions.
9. Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment. Participants with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance, or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.

10. Treatment with one of the following classes of drugs within the delineated time window prior to Cycle 1 Day 1 (C1D1):

    1. Cytotoxic, targeted therapy or other investigational therapy within 3 weeks.
    2. Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar therapy, within 4 weeks, or 5 half-lives, whichever is shorter.
    3. Small molecule/tyrosine kinase inhibitors within 2 weeks or less than 5 circulating half-lives of investigational drug.
11. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
12. Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.
13. History of allogeneic organ transplant, stem cell transplant, or bone marrow transplant.
14. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
15. Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
16. Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (that is, with use of disease-modifying agents or immunosuppressive drugs).
17. History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
18. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.
19. Uncontrolled infection with human immunodeficiency virus.
20. Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection.
21. Known active hepatitis C virus as determined by positive serology and confirmed by polymerase chain reaction.
22. Has urine protein ≥ 1 gram/24 hour.
23. Uncontrolled hypertension: systolic pressure ≥ 150 millimeters of mercury (mmHg) or diastolic pressure ≥ 90 mmHg on repeated measurements that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug(s).
24. Participants who require treatment with strong cytochrome P450 3A4 inducers or inhibitors.
25. Has presence of gastrointestinal condition, for example, malabsorption, that might affect the absorption of study drug(s).
26. Non-healing wound(s).
27. Symptomatic active bleeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Combination Botensilimab Dose 1 plus Balstilimab; Participants will receive botensilimab at dose 1 given IV and balstilimab given IV.	Drug: Botensilimab; An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.; Other Names: AGEN1181; Drug: Balstilimab; An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody.; Other Names: AGEN2034
Experimental: Combination Botensilimab Dose 2 plus Balstilimab; Participants will receive botensilimab at dose 2 given IV and balstilimab given IV.	Drug: Botensilimab; An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.; Other Names: AGEN1181; Drug: Balstilimab; An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody.; Other Names: AGEN2034
Experimental: Monotherapy Botensilimab Dose 1; Participants will receive botensilimab dose 1 given IV.	Drug: Botensilimab; An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.; Other Names: AGEN1181
Experimental: Monotherapy Botensilimab Dose 2; Participants will receive botensilimab dose 2 given IV.	Drug: Botensilimab; An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.; Other Names: AGEN1181
Active Comparator: Standard of Care; Participants will receive select standard of care as determined by the investigator.	Drug: Standard of Care; Regorafenib or trifluridine and tipiracil.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate	Objective response rate is defined as the proportion of participants with complete response or partial response, as assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).	First dose through up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Response	Duration of response is defined as the time from initial objective radiographic response until disease progression or death, whichever occurs first, as assessed using RECIST 1.1.	First dose through up to 2 years
Progression-free Survival	Progression-free survival is defined as the time from randomization until disease progression or death, whichever occurs first, as assessed using RECIST 1.1.	First dose through up to 3 years
Overall Survival	Overall survival is defined as the time from randomization until death due to any cause.	First dose through up to 3 years
Number of Participants Experiencing Treatment-emergent Adverse Events		First dose through up to 2 years
Serum Botensilimab Concentration		First study dose (pre-dose and 1 hour post-dose) through up to 2 years
Serum Balstilimab Concentration		First study dose (pre-dose and 1 hour post-dose) through up to 2 years
Number of Participants Positive for Botensilimab Anti-drug Antibodies Following Treatment with Botensilimab		First study dose (pre-dose and 1 hour post-dose) through up to 2 years
Number of Participants Positive for Balstilimab Anti-drug Antibodies Following Treatment with Balstilimab		First study dose (pre-dose and 1 hour post-dose) through up to 2 years

Collaborators and Investigators

• Sponsor: Agenus Inc.
• Investigators: Study Director: Medical Director, Agenus Inc.

Study record dates

Study Major Dates

• Study Start (Actual): November 30, 2022
• Primary Completion (Estimated): February 1, 2025
• Study Completion (Estimated): July 1, 2025

Study Registration Dates

• First Submitted: November 1, 2022
• First Submitted That Met QC Criteria: November 1, 2022
• First Posted (Actual): November 8, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2024
• Last Update Submitted That Met QC Criteria: March 22, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Immunotherapy; Colorectal Cancer; Regorafenib; Balstilimab; AGEN2034; CTLA-4; Open Label; Botensilimab; AGEN1181; Trifluridine; Tipiracil; Lonsurf; Pd-1; Fc-enhanced; Agenus; MSS; Microsatellite stable
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: C-800-25; 2022-501546-29 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No